Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| Edgewise Therapeutics Inc.COM | COM | $630,516,330 | 11.7% |
| Enliven Therapeutics Inc.COM | COM | $343,914,074 | 6.4% |
| Eli Lilly & COCOM | COM | $309,332,997 | 5.7% |
| Mbx Biosciences Inc.COM | COM | $189,266,227 | 3.5% |
| Sinovac Biotech LtdSHS | SHS | $184,466,170 | 3.4% |
| Astrazeneca PLCORD | ORD | $171,079,502 | 3.2% |
| Structure Therapeutics Inc.SPONSORED ADS | SPONSORED ADS | $118,578,498 | 2.2% |
| Sionna Therapeutics Inc.COM | COM | $112,433,029 | 2.1% |
| Corvus Pharmaceuticals Inc.COM | COM | $107,045,190 | 2.0% |
| Arrivent Biopharma Inc.COM | COM | $105,169,375 | 1.9% |
| Guardant Health Inc.COM | COM | $87,572,511 | 1.6% |
| Argenx SESPONSORED ADR | SPONSORED ADR | $86,171,278 | 1.6% |
| Merck & CO Inc.COM | COM | $85,246,900 | 1.6% |
| Uniqure NVSHS | SHS | $83,252,805 | 1.5% |
| Praxis Precision Medicines ICOM NEW | COM NEW | $77,035,179 | 1.4% |
| Edwards Lifesciences Corp.COM | COM | $75,525,054 | 1.4% |
| Prelude Therapeutics Inc.COM | COM | $73,151,963 | 1.4% |
| Abivax SASPONSORED ADS | SPONSORED ADS | $72,829,522 | 1.3% |
| Dyne Therapeutics Inc.COM | COM | $71,864,542 | 1.3% |
| Natera Inc.COM | COM | $71,119,900 | 1.3% |
| CG Oncology Inc.COM | COM | $69,117,440 | 1.3% |
| Unitedhealth Group Inc.COM | COM | $66,957,993 | 1.2% |
| Ars Pharmaceuticals Inc.COM | COM | $66,390,965 | 1.2% |
| Ascendis Pharma A/sORD SHS | ORD SHS | $65,201,304 | 1.2% |
| Humana Inc.COM | COM | $65,183,802 | 1.2% |
| Cogent Biosciences Inc.COM | COM | $65,066,310 | 1.2% |
| Boston Scientific Corp.COM | COM | $63,302,976 | 1.2% |
| Intuitive Surgical Inc.COM NEW | COM NEW | $62,793,672 | 1.2% |
| Mineralys Therapeutics Inc.COM | COM | $56,935,894 | 1.1% |
| Odyssey Therapeutics Inc.COMMON STOCK | COMMON STOCK | $56,152,415 | 1.0% |
| Xenon Pharmaceuticals Inc.COM | COM | $53,869,550 | 1.0% |
| Arcutis Biotherapeutics Inc.COM | COM | $53,541,240 | 1.0% |
| Bristol-myers Squibb COCOM | COM | $53,298,500 | 1.0% |
| Q32 Bio Inc.COM | COM | $52,590,554 | 1.0% |
| Stryker CorporationCOM | COM | $50,091,044 | 0.9% |
| Caris Life Sciences Inc.COM | COM | $50,017,372 | 0.9% |
| SPDR Series Trust (put option)ST STR SP BIOT | ST STR SP BIOT | $47,475,000 | 0.9% |
| Thermo Fisher Scientific Inc.COM | COM | $45,473,352 | 0.8% |
| Palvella Therapeutics Inc. NECOM | COM | $44,678,455 | 0.8% |
| Elevance Health Inc. FormerlyCOM | COM | $44,357,931 | 0.8% |
| Shattuck Labs Inc.COM | COM | $43,764,521 | 0.8% |
| Upstream Bio Inc.COM | COM | $39,399,636 | 0.7% |
| Crinetics Pharmaceuticals INCOM | COM | $37,382,580 | 0.7% |
| Rhythm Pharmaceuticals Inc.COM | COM | $35,851,587 | 0.7% |
| Syndax Pharmaceuticals Inc.COM | COM | $33,708,120 | 0.6% |
| Forte Biosciences Inc.COM NEW | COM NEW | $33,526,231 | 0.6% |
| Compass Therapeutics Inc.COM | COM | $33,331,787 | 0.6% |
| Nektar TherapeuticsCOM NEW | COM NEW | $32,485,804 | 0.6% |
| Krystal Biotech Inc.COM | COM | $30,922,944 | 0.6% |
| Prelude Therapeutics Inc.NON VOTING | NON VOTING | $30,275,391 | 0.6% |
Edgewise Therapeutics Inc.COM$630,516,330
- Class
- COM
- Share
- 11.7%
Enliven Therapeutics Inc.COM$343,914,074
- Class
- COM
- Share
- 6.4%
Eli Lilly & COCOM$309,332,997
- Class
- COM
- Share
- 5.7%
Mbx Biosciences Inc.COM$189,266,227
- Class
- COM
- Share
- 3.5%
Sinovac Biotech LtdSHS$184,466,170
- Class
- SHS
- Share
- 3.4%
Astrazeneca PLCORD$171,079,502
- Class
- ORD
- Share
- 3.2%
Structure Therapeutics Inc.SPONSORED ADS$118,578,498
- Class
- SPONSORED ADS
- Share
- 2.2%
Sionna Therapeutics Inc.COM$112,433,029
- Class
- COM
- Share
- 2.1%
Corvus Pharmaceuticals Inc.COM$107,045,190
- Class
- COM
- Share
- 2.0%
Arrivent Biopharma Inc.COM$105,169,375
- Class
- COM
- Share
- 1.9%
Guardant Health Inc.COM$87,572,511
- Class
- COM
- Share
- 1.6%
Argenx SESPONSORED ADR$86,171,278
- Class
- SPONSORED ADR
- Share
- 1.6%
Merck & CO Inc.COM$85,246,900
- Class
- COM
- Share
- 1.6%
Uniqure NVSHS$83,252,805
- Class
- SHS
- Share
- 1.5%
Praxis Precision Medicines ICOM NEW$77,035,179
- Class
- COM NEW
- Share
- 1.4%
Edwards Lifesciences Corp.COM$75,525,054
- Class
- COM
- Share
- 1.4%
Prelude Therapeutics Inc.COM$73,151,963
- Class
- COM
- Share
- 1.4%
Abivax SASPONSORED ADS$72,829,522
- Class
- SPONSORED ADS
- Share
- 1.3%
Dyne Therapeutics Inc.COM$71,864,542
- Class
- COM
- Share
- 1.3%
Natera Inc.COM$71,119,900
- Class
- COM
- Share
- 1.3%
CG Oncology Inc.COM$69,117,440
- Class
- COM
- Share
- 1.3%
Unitedhealth Group Inc.COM$66,957,993
- Class
- COM
- Share
- 1.2%
Ars Pharmaceuticals Inc.COM$66,390,965
- Class
- COM
- Share
- 1.2%
Ascendis Pharma A/sORD SHS$65,201,304
- Class
- ORD SHS
- Share
- 1.2%
Humana Inc.COM$65,183,802
- Class
- COM
- Share
- 1.2%
Cogent Biosciences Inc.COM$65,066,310
- Class
- COM
- Share
- 1.2%
Boston Scientific Corp.COM$63,302,976
- Class
- COM
- Share
- 1.2%
Intuitive Surgical Inc.COM NEW$62,793,672
- Class
- COM NEW
- Share
- 1.2%
Mineralys Therapeutics Inc.COM$56,935,894
- Class
- COM
- Share
- 1.1%
Odyssey Therapeutics Inc.COMMON STOCK$56,152,415
- Class
- COMMON STOCK
- Share
- 1.0%
Xenon Pharmaceuticals Inc.COM$53,869,550
- Class
- COM
- Share
- 1.0%
Arcutis Biotherapeutics Inc.COM$53,541,240
- Class
- COM
- Share
- 1.0%
Bristol-myers Squibb COCOM$53,298,500
- Class
- COM
- Share
- 1.0%
Q32 Bio Inc.COM$52,590,554
- Class
- COM
- Share
- 1.0%
Stryker CorporationCOM$50,091,044
- Class
- COM
- Share
- 0.9%
Caris Life Sciences Inc.COM$50,017,372
- Class
- COM
- Share
- 0.9%
SPDR Series Trust (put option)ST STR SP BIOT$47,475,000
- Class
- ST STR SP BIOT
- Share
- 0.9%
Thermo Fisher Scientific Inc.COM$45,473,352
- Class
- COM
- Share
- 0.8%
Palvella Therapeutics Inc. NECOM$44,678,455
- Class
- COM
- Share
- 0.8%
Elevance Health Inc. FormerlyCOM$44,357,931
- Class
- COM
- Share
- 0.8%
Shattuck Labs Inc.COM$43,764,521
- Class
- COM
- Share
- 0.8%
Upstream Bio Inc.COM$39,399,636
- Class
- COM
- Share
- 0.7%
Crinetics Pharmaceuticals INCOM$37,382,580
- Class
- COM
- Share
- 0.7%
Rhythm Pharmaceuticals Inc.COM$35,851,587
- Class
- COM
- Share
- 0.7%
Syndax Pharmaceuticals Inc.COM$33,708,120
- Class
- COM
- Share
- 0.6%
Forte Biosciences Inc.COM NEW$33,526,231
- Class
- COM NEW
- Share
- 0.6%
Compass Therapeutics Inc.COM$33,331,787
- Class
- COM
- Share
- 0.6%
Nektar TherapeuticsCOM NEW$32,485,804
- Class
- COM NEW
- Share
- 0.6%
Krystal Biotech Inc.COM$30,922,944
- Class
- COM
- Share
- 0.6%
Prelude Therapeutics Inc.NON VOTING$30,275,391
- Class
- NON VOTING
- Share
- 0.6%
The share class is shown on a wider screen.
The 50 largest of 129 positions by value, with holdings of the same security combined. The 129 largest are in this firm's machine-readable record. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 1055951
- File number
- 028-06774
- Options
- 6 call, 2 put
- In the 25 largest
- 62.8%
- Prior quarter
- $5,045,363,608 at 31 March 2026
- Positions opened
- 42
- Positions closed
- 25
Common questions
What are Orbimed Advisors’ 13F holdings worth?
$5,396,779,685 across 129 positions for the quarter ended 30 June 2026.
What is Orbimed Advisors’ largest 13F holding?
EDGEWISE THERAPEUTICS INC (COM) was the largest position at $630,516,330, or 11.7% of reported 13F value, as of 30 June 2026.
How concentrated is Orbimed Advisors’ 13F portfolio?
The ten largest positions accounted for 42.1% of reported value and the twenty-five largest for 62.8%, across 129 positions as of 30 June 2026.
Does Form 13F show everything Orbimed Advisors manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Orbimed Advisors file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.